Hoyoung Huh, MD, PhD
Hoyoung Huh, MD, PhD, is the founder of Peak Bio Inc. (f/k/a pH Pharma) and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015. He currently serves as a director on the board of directors (the “Board”) of the Company. Dr. Huh is a Silicon Valley-based entrepreneur and investor in healthcare and technology-based businesses and has served as Lead Director of Pliant Therapeutics since December 2017. Dr. Huh was a Managing Director of Konus Advisory Group, Inc. from January 2012 to September 2014. Prior to founding Konus Advisory Group, Inc., Dr. Huh was Chief Executive Officer and Chairman of the board of directors of BiPar Sciences, Inc. from February 2008 until December 2010. In addition, Dr. Huh has been involved in the formation, management and board positions of multiple biotechnology and innovation-based companies. He previously served as the Chairman of the board of directors of Geron Corporation from September 2011 to December 2018, and CytomX Therapeutics, Inc. from February 2012 to December 2018, a member of the board of directors of Rezolute, Inc. (f/k/a AntriaBio, Inc.) from 2013 to January 2019, the Chairman of the board of directors of Epizyme, Inc. from October 2009 to February 2012, and as a member of the board of directors of Facet Biotech Corporation, Nektar Therapeutics, Inc., Addex Therapeutics Ltd. and EOS, S.p.A (Milano, Italy). Earlier in his career, Dr. Huh was a partner at McKinsey & Company. He holds A.B. in Biochemistry from Dartmouth College, an M.D. from Cornell University Medical College and a Ph.D. in Cell Biology and Genetics from Cornell University Sloan Kettering Institute. We believe Dr. Huh’s extensive management and operational experience as President and Chief Executive Officer of numerous biotechnology companies and his significant knowledge and expertise of biotechnology and pharmaceutical collaborations, qualifies Dr. Huh to serve as a director and Chairman of the Board of Peak Bio Inc..
Stephen LaMond, PharmD, MBA
Stephen LaMond, PharmD, MBA, has been the Chief Operating Officer and Secretary of Peak Bio Inc. since March 1, 2022. He currently serves as Interim Chief Executive Officer and as a director of the Company. Prior to his current role, Dr. LaMond has been both an employee and independent consultant to Peak Bio (f/k/a pH Pharma). Peak Bio consists of the merged entity of Ignyte and the selected assets from pH Pharma. Dr. LaMond served as both a consultant and one of the original executives with pH Pharma and its affiliated companies serving in corporate and business development roles in addition to serving in a clinical program management capacity. Dr. LaMond has been directly involved with pH Pharma in both the U.S. and Korea and now at Peak Bio since 2016. Dr. LaMond has previously held management and executive roles in marketing, new product planning, corporate and business development at numerous companies including Tria Beauty, Corium International, Zoll Medical, GE Healthcare, Nektar Therapeutics and Pfizer Inc. across multiple therapeutic areas and has worked on some of the most innovative products over his tenure. Dr. LaMond received his PharmD and Executive MBA degrees from the University of Michigan, Ann Arbor and has executive finance training from Columbia and Stanford Universities. We believe Dr. LaMond’s extensive experience in operations, business development, corporate development, marketing, regulatory and market access with biopharmaceutical and biotechnology companies qualifies him to serve on the Board.
Satyajit Mitra, PhD
Satyajit Mitra, PhD, is the Executive Director and Head of Oncology for Peak Bio Inc.. As the Head of Oncology, he has been responsible for Peak Bio Inc.’s preclinical research activities at our CA research sites since January 2021. Dr. Mitra heads up a team of talented research associates, scientists, consultants, CROs and CDMOs and has been instrumental in advancing our novel toxin platform and ADC pipeline. From March 2019 to December 2020, Dr. Mitra headed up Cancer Biology at Peak Bio Inc. and was responsible for in vivo and pharmacology functions that led to the nomination of the current Peak Bio lead toxin (PH1), which then led to Peak Bio’s initial proof-of-concept (POC) efforts for an ADC. These POC efforts led to the nomination of Peak Bio’s first ADC pipeline candidate targeting Trop2. He previously served as a Senior Scientist, at VasGene Therapeutics, and was involved with IND-enabling studies for novel antibody targets. Dr. Mitra’s initial corporate scientific experience was at OncoMed Pharmaceuticals for 5 years where he worked on Target Validation. He was instrumental in identifying the first-in-class Wnt-pathway biologics, advancing these projects from early stage to an IND. In addition to Dr. Mitra’s oncology company experiences, he also previously worked as a research scientist at the University of Southern California in Los Angeles. He completed his postdoctoral fellowship at the Department of Immunology at Scripps Research Institute at La Jolla, California. He obtained his Ph.D. from the Centre for Cellular and Molecular Biology at Hyderabad, India an institute affiliated with the Jawaharlal Nehru University (JNU), New Delhi, India.
Peter McCabe, JD is the General Counsel of Peak Bio, Inc. Mr. McCabe has been a principal with BC Burr McCabe Law since 2010, where he provides business and legal advice to established and emerging companies regarding intellectual property licensing, corporate, commercial and financial matters. Previously, he served in a number of executive and legal roles, including founder and CEO of Wireless Glue Networks, outside corporate counsel to Redwood Trust. (NYSE: RWT), Vice President, General Counsel and Chief Administrative Officer for Tiburon, Inc., director of legal affairs for Engenio Information Technologies, and as a corporate lawyer with Latham & Watkins. Mr. McCabe received a JD from U.C. Berkeley, Boalt Hall, and a BS in Finance from Cal Poly, San Luis Obispo, California.
Timothy Cunningham, MBA, CPA
Timothy Cunningham, MBA, CPA, serves as the Acting Chief Financial Officer of the Company following the closing of the Business Combination. He brings more than 30 years of finance and operations leadership experience in the life sciences and technology industries with a proven track record of driving growth. He is currently Chief Financial Officer at Danforth Advisors, a company that provides strategic and operational finance and accounting support for life science companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis, where he took the company public and raised over $250M in equity and debt financing to facilitate the company’s growth. Earlier, he held leadership positions with DialogTech, GFI Software SA, Metatomix, Mediabridge, IBM, PWC, and KPMG. Tim holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida.
Divya Patel serves as Corporate Controller of Peak Bio Inc. In this role, she has overall responsibility for the financial reporting activities for Peak Bio Inc. and its global subsidiaries. She has served as controller and treasurer in the private sector for medical device companies including the international brand Tria Beauty. Ms. Patel has over 10 years experience in finance and accounting experience and holds a Certified Public Accountant designation. Ms. Patel has also served as an auditor and international tax manager with accounting firms in Canada, including Canadian national firm MNP LLP. She obtained her Bachelors in Business Administration from Simon Fraser University and also holds a Chartered Professional Accounting Designation in Canada.
Moddy joined the company in December 2022 as the Director of Human Resources. She has over 18 years of experience in Human Resources, most recently in the Biotech/Medical Device spaces. Moddy is a collaborative HR leader who enjoys face-paced, innovative workplaces and cultivating an impactful and differentiated culture. She is passionate about the employee experience, building out talent management and culture infrastructures to enable growth while incorporating inclusion and fun.